JP2009543802A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543802A5
JP2009543802A5 JP2009519653A JP2009519653A JP2009543802A5 JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5 JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5
Authority
JP
Japan
Prior art keywords
nrr
nhr
acyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073285 external-priority patent/WO2008008854A2/en
Publication of JP2009543802A publication Critical patent/JP2009543802A/ja
Publication of JP2009543802A5 publication Critical patent/JP2009543802A5/ja
Pending legal-status Critical Current

Links

JP2009519653A 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト Pending JP2009543802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83000606P 2006-07-11 2006-07-11
US81999706P 2006-07-11 2006-07-11
PCT/US2007/073285 WO2008008854A2 (en) 2006-07-11 2007-07-11 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders

Publications (2)

Publication Number Publication Date
JP2009543802A JP2009543802A (ja) 2009-12-10
JP2009543802A5 true JP2009543802A5 (cg-RX-API-DMAC7.html) 2011-09-01

Family

ID=38924159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519653A Pending JP2009543802A (ja) 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト

Country Status (4)

Country Link
US (1) US8080659B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041067A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009543802A (cg-RX-API-DMAC7.html)
WO (1) WO2008008854A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008312B2 (en) * 2005-01-07 2011-08-30 Emory University CXCR4 antagonists for the treatment of HIV infection
CA2718618A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2011094389A2 (en) * 2010-01-27 2011-08-04 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
DK2776387T3 (en) 2011-11-07 2017-05-08 Univ Emory Tricyclic amino containing compounds to treat or prevent symptoms associated with endocrine dysfunction
WO2013096926A1 (en) 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
ES2668045T3 (es) 2012-12-07 2018-05-16 Glycomimetics, Inc. Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
AU2014396468B2 (en) 2014-06-06 2019-02-21 Technische Universitat Munchen Modified cyclopentapeptides and uses thereof
US10519181B2 (en) 2014-12-03 2019-12-31 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
WO2017023999A1 (en) * 2015-08-03 2017-02-09 Emory University Methylsulfonamide derivatives and uses related thereto
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
EP3522931A1 (en) 2016-10-07 2019-08-14 GlycoMimetics, Inc. Highly potent multimeric e-selectin antagonists
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス, インコーポレイテッド E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
MA55385A (fr) * 2019-03-22 2022-01-26 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776465A (en) * 1904-04-15 1904-11-29 Charles A Gildemeyer Spigot.
US5993817A (en) * 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
WO1997000956A1 (en) 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5874438A (en) * 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
US6534626B1 (en) * 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
EP1061944B1 (en) 1998-03-13 2004-01-28 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
AU4550699A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
AU1408300A (en) * 1998-11-24 2000-06-13 Hisamitsu Pharmaceutical Co. Inc. Hiv infection inhibitors
PL350998A1 (en) 1999-03-24 2003-02-24 Anormed Inc Chemokine recpetor binding heterocyclic compounds
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU1488501A (en) 1999-11-24 2001-06-04 Schering Corporation Methods of inhibiting metastasis
US20030220482A1 (en) 2000-02-03 2003-11-27 Ziwei Huang Novel peptide antagonist of CXCR4 derived from the N-terminus of the viral chemokine vMIP-II
WO2001070727A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
ATE265219T1 (de) 2000-05-09 2004-05-15 Univ British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2002002516A2 (en) * 2000-06-30 2002-01-10 Thomas Jefferson University Inhibitors of hiv integrase
JPWO2002094261A1 (ja) 2001-05-24 2004-09-02 呉羽化学工業株式会社 含窒素化合物からなるcxcr4拮抗作用を有する薬剤
JPWO2003029218A1 (ja) * 2001-09-28 2005-01-13 呉羽化学工業株式会社 新規含窒素化合物及びその用途
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004087068A2 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
BRPI0409655B8 (pt) 2003-04-22 2021-05-25 Anormed Inc compostos heterocíclicos de ligação ao receptor para quimiocina com maior eficiência
US7683061B2 (en) * 2003-11-24 2010-03-23 Prometic Biosciences Inc. Triazine dimers for the treatment of autoimmune diseases
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
RU2007130077A (ru) * 2005-01-07 2009-02-20 Эмори Юниверсити (Us) Антагонисты cxcr4 и их применение для лечения вич-инфекции
US8008312B2 (en) * 2005-01-07 2011-08-30 Emory University CXCR4 antagonists for the treatment of HIV infection
US20080227799A1 (en) * 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders

Similar Documents

Publication Publication Date Title
JP2009543802A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2018158926A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2014193925A5 (cg-RX-API-DMAC7.html)
JP2009535307A5 (cg-RX-API-DMAC7.html)
JP2008525416A5 (cg-RX-API-DMAC7.html)
JP2016006096A5 (cg-RX-API-DMAC7.html)
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2016514192A5 (cg-RX-API-DMAC7.html)
JP2009536221A5 (cg-RX-API-DMAC7.html)
JP2011500713A5 (cg-RX-API-DMAC7.html)
JP2008539267A5 (cg-RX-API-DMAC7.html)
JP2013507423A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2009537550A5 (cg-RX-API-DMAC7.html)
JP2013544276A5 (cg-RX-API-DMAC7.html)
JP2015529228A5 (cg-RX-API-DMAC7.html)
JP2017528475A5 (cg-RX-API-DMAC7.html)
JP2009541225A5 (cg-RX-API-DMAC7.html)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2009500423A5 (cg-RX-API-DMAC7.html)